Overview

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, Phase Ib study to be conducted at approximately eight sites in Europe and the U.S. designed to evaluate the safety, pharmacokinetics, and activity of SGN-40 when combined with bortezomib in patients with multiple myeloma that is relapsed or refractory after at least one prior systemic treatment regimen.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Collaborators:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Bortezomib